AMGN241227C280000
- 0.04
- +0.02+100.00%
Amgen Newsroom
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Is Amgen (NASDAQ:AMGN) a High-Quality Dividend Stock on Sale?
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025
Sector Update: Health Care Stocks Advance Late Afternoon
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Spotlight on Amgen: Analyzing the Surge in Options Activity
Lilly, Amgen Sue HHS Over Certification of Drug Discount Program Recipients
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
What's Going On With Amgen Stock On Friday?
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $350
Goldman Sachs, Salesforce Share Gains Lead Dow's 300-Point Jump
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Why Is Novo Nordisk Crashing After Data for Next-gen Weight Loss Drug?
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations
Amgen Shares Are Trading Higher. Weight-loss Related Stocks Are up on Friday Following Weaker-than-expected Data From Competitor Lilly.
Express News | Amgen Shares up 5.3% Premarket After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Low-Volatility Funds From Vanguard and Others Sound Ideal for This Market. Why They Might Not Be.
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating